Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
Tianjin Medical University Cancer Institute and Hospital
Vanderbilt-Ingram Cancer Center
Sichuan University
Spanish Lung Cancer Group
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Swiss Cancer Institute
Fox Chase Cancer Center
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Spectrum Pharmaceuticals, Inc
Accuray Incorporated
AIO-Studien-gGmbH
Odense University Hospital
H. Lee Moffitt Cancer Center and Research Institute
Medstar Health Research Institute
Shanghai Cancer Hospital, China
Tetra Bio-Pharma
Zhejiang Cancer Hospital
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Swiss Cancer Institute
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Swedish Orphan Biovitrum
Alliance for Clinical Trials in Oncology
University of Miami
Alliance for Clinical Trials in Oncology
Japan Clinical Oncology Group
Centre Henri Becquerel
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology